Salarius Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Salarius Pharmaceuticals Inc cash flow-to-debt ratio. Salarius Pharmaceuticals Inc (SLRX) has a Cash Flow-to-Debt Ratio of -0.89x as of September 2025, meaning its operating cash flow of $-1.65 Million could theoretically repay -1% of its total liabilities ($1.85 Million) in one year. See SLRX financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Salarius Pharmaceuticals Inc (2015–2024)
Cash flow-to-debt ratio of Salarius Pharmaceuticals Inc from 2015 to 2024. Historical debt coverage capacity for Salarius Pharmaceuticals Inc across 10 annual periods. Also explore Salarius Pharmaceuticals Inc annual equity growth to track the company's year-over-year net asset growth rate.
Salarius Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2015–2024)
Salarius Pharmaceuticals Inc cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Salarius Pharmaceuticals Inc. For the full cash flow conversion analysis, see cash flow conversion of Salarius Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.99x | $-4.53 Million | $1.51 Million | ▲ +69.7% |
| 2023 | -9.89x | $-12.85 Million | $1.30 Million | ▼ -139.7% |
| 2022 | -4.12x | $-17.60 Million | $4.27 Million | ▲ +14.6% |
| 2021 | -4.83x | $-10.20 Million | $2.11 Million | ▼ -30.0% |
| 2020 | -3.72x | $-10.31 Million | $2.77 Million | ▼ -6.4% |
| 2019 | -3.49x | $-11.58 Million | $3.31 Million | ▲ +83.6% |
| 2018 | -21.32x | $-23.60 Million | $1.11 Million | ▼ -352.7% |
| 2017 | -4.71x | $-27.72 Million | $5.89 Million | ▲ +42.7% |
| 2016 | -8.22x | $-32.05 Million | $3.90 Million | ▼ -14.1% |
| 2015 | -7.21x | $-20.75 Million | $2.88 Million | — |